CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-16 | Howarth Alex G. Chief Financial Officer | Shares withheld for taxes | −1,067 | $243.92 | $260K | 13,934 |
| 2023-12-15 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise | +2,000 | $87.92 | $176K | 7,667 |
| 2023-12-15 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,000 | $236.00 | $236K | 6,667 |
| 2023-12-15 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,000 | $241.00 | $241K | 5,667 |
| 2023-12-15 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise · Stock Option (Right to Buy) | −2,000 | 17,200 | ||
| 2023-12-14 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise | +2,000 | $87.92 | $176K | 7,667 |
| 2023-12-14 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,000 | $233.00 | $233K | 6,667 |
| 2023-12-14 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,000 | $232.00 | $232K | 5,667 |
| 2023-12-14 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise · Stock Option (Right to Buy) | −2,000 | 19,200 | ||
| 2023-12-14 | BAKER BROS. ADVISORS LP Director | Purchase | +107 | $226.97 | $24K | 184,562 |
| 2023-12-14 | BAKER BROS. ADVISORS LP Director | Purchase | +1,343 | $226.97 | $305K | 1,775,637 |
| 2023-12-14 | BAKER BROS. ADVISORS LP Director | Purchase | +925 | $227.86 | $211K | 185,487 |
| 2023-12-14 | BAKER BROS. ADVISORS LP Director | Purchase | +11,602 | $227.86 | $2.6M | 1,787,239 |
| 2023-12-14 | BAKER BROS. ADVISORS LP Director | Purchase | +176 | $228.79 | $40K | 185,663 |
| 2023-12-14 | BAKER BROS. ADVISORS LP Director | Purchase | +2,204 | $228.79 | $504K | 1,789,443 |
| 2023-12-14 | BAKER BROS. ADVISORS LP Director | Purchase | +316 | $229.86 | $73K | 185,979 |
| 2023-12-14 | BAKER BROS. ADVISORS LP Director | Purchase | +3,960 | $229.86 | $910K | 1,793,403 |
| 2023-12-13 | BAKER BROS. ADVISORS LP Director | Purchase | +818 | $216.70 | $177K | 179,279 |
| 2023-12-13 | BAKER BROS. ADVISORS LP Director | Purchase | +10,264 | $216.70 | $2.2M | 1,709,393 |
| 2023-12-13 | BAKER BROS. ADVISORS LP Director | Purchase | +869 | $217.52 | $189K | 180,148 |
Page 38 of 82 · 1,629 trades